Biotechnology Regenerative Organ Patent Law In Russia.
1. Introduction
Regenerative organ patent law in Russia concerns the legal protection of scientific inventions involving the creation, reconstruction, repair, replacement, and regeneration of human organs and biological tissues.
It covers emerging biotechnology techniques such as:
3D-bioprinted organs and tissues.
Artificially engineered organs.
Stem-cell-based organ regeneration.
Regenerative medicine and tissue engineering.
Bioengineered skin, cartilage, bone, liver, kidney, and cardiac tissues.
Organoids and laboratory-grown biological structures.
Biomaterials and biodegradable scaffolds.
Gene-edited cells used in regenerative therapies.
Methods for repairing damaged organs.
Russia does not have a single statute exclusively governing regenerative-organ patents. Instead, protection is determined through a combination of Russian civil patent law, biotechnology regulation, medical-product legislation, human-subject protections, and rules governing the use of biological materials.
The central legal question is whether an invention involving biological material or regenerative technology qualifies for patent protection without violating restrictions concerning the human body, human embryos, genetic modification, and medical treatment.
2. Legal framework governing regenerative-organ patents
The principal legislation is Part IV of the Russian Civil Code, particularly Articles 1349–1363.
A. Article 1349 – Objects excluded from patent protection
Article 1349(4) establishes important ethical restrictions. Patent protection cannot be granted to:
Methods of human cloning and human clones.
Methods of modifying the genetic integrity of human germline cells.
Use of human embryos for industrial and commercial purposes.
Intellectual results contrary to public interests, humanity, and morality.
These restrictions are particularly important for regenerative-organ biotechnology.
However, they do not create a blanket prohibition on patenting regenerative medicine. For example, a process for growing a patient's skin cells, a synthetic organ scaffold, or a bioengineered tissue may qualify for patent protection if it satisfies the statutory requirements.
USPTO+2
B. Article 1350 – Patentability requirements
A regenerative-organ invention must satisfy three essential conditions:
Novelty: The invention must not already be publicly known.
Inventive step: It must not be an obvious technical development for a specialist in the relevant field.
Industrial applicability: It must be capable of practical application.
Article 1350 recognises technical solutions relating to products and processes, including substances, devices, and cell cultures.
Accordingly, patent applications may cover:
A new biodegradable organ scaffold.
A bioreactor for growing replacement organs.
A method of producing vascularised artificial tissue.
A specially engineered cell culture.
A bioink composition for organ printing.
Consultant Plus+1
C. Article 1351 – Utility models
Utility-model protection may be relevant to technical devices used in regenerative medicine, such as specialised bioreactor components, tissue-supporting devices, and certain medical instruments, subject to the statutory requirements.
It is important to distinguish protection for a technical device from protection for the biological tissue itself.
D. Articles 1354–1363 – Patent rights and enforcement
These provisions form part of the wider framework governing patent documentation, exclusive rights, the term of protection, and the legal consequences of patent infringement.
The patent holder may generally prevent unauthorised commercial exploitation of the patented invention, subject to statutory limitations and exceptions.
3. What regenerative-organ technologies can be patented?
| Technology | Potential patent protection |
|---|---|
| 3D-bioprinted organ scaffold | Yes, if patentable |
| Artificial kidney-support device | Yes |
| Engineered cardiac tissue | Potentially |
| Stem-cell culture process | Potentially |
| Biodegradable biomaterial | Yes, if patentable |
| Organ regeneration bioreactor | Yes |
| Human cloning method | Excluded |
| Commercial use of human embryos | Excluded |
| Germline genetic-integrity modification method | Excluded |
An important distinction exists between a naturally occurring biological discovery and a technically developed invention.
Simply discovering that a particular human cell can regenerate tissue does not automatically establish patentability. However, a technically defined and reproducible method for isolating, culturing, modifying, or applying cells may qualify, provided it complies with Russian law.
4. Stem cells and regenerative-organ patent protection
Stem cells are particularly important because they may differentiate into specialised cells capable of repairing or replacing damaged tissues.
Russian patent law does not categorically prohibit all inventions involving human stem cells.
Potentially protectable inventions include:
Stem-cell isolation and purification techniques.
Cell-expansion technologies.
Differentiation protocols.
Cell-supporting biomaterials.
Tissue-engineering compositions.
Methods of manufacturing regenerative cellular products.
However, patentability must be distinguished from the legality of obtaining and using biological material.
For example, an invention involving human embryonic material must be examined carefully under Article 1349(4), particularly the prohibition on industrial and commercial uses of human embryos.
A patent cannot legitimise an otherwise unlawful biological procedure.
5. Biomedical Cellular Products Law, 2016 (Federal Law No. 180-FZ)
The Federal Law No. 180-FZ of 23 June 2016, concerning Biomedical Cellular Products, is an important part of Russia's regenerative medicine framework.
It regulates:
Development of biomedical cellular products.
Preclinical research.
Clinical investigations.
Ethical and scientific examination.
State registration.
Manufacturing and quality control.
Storage and transportation.
Biological-material donation.
Product safety and liability.
Under Article 8, biomedical cellular products generally require state registration before commercial production, sale, application, storage, and other regulated activities, subject to statutory exceptions.
Article 33 addresses obtaining biological material, while Article 34 establishes rights and obligations of donors and their legal representatives.
Article 48 addresses compensation for injury to life or health resulting from the use of biomedical cellular products.
Consultant Plus+2
Important limitation: Article 1(2) excludes organ and human-tissue donation for transplantation from the scope of Law No. 180-FZ. Consequently, a conventional organ transplant and a manufactured regenerative cellular product may fall under different regulatory regimes.
ГАРАНТ+1
6. Patent protection for 3D-bioprinted organs
Bioprinting turns reliable alternative for testing new drugs
Frontiers | The sculpting tool in bioprinting: research and application progress of sacrificial inks
10
3D bioprinting is an emerging technology that uses living cells, biomaterials, and specialised printing equipment to construct biological structures.
In Russia, different components of this technology may receive separate patent protection.
A. Bioink composition
A novel bioink containing a specific combination of hydrogel, biological cells, and growth-supporting materials may qualify as a patentable composition.
B. Bioprinting equipment
A new printing nozzle, cell-positioning mechanism, or temperature-controlled bioprinter may qualify as an invention or, where appropriate, a utility model.
C. Organ scaffold
A biodegradable scaffold designed to support the development of liver, kidney, or cardiac tissue may qualify if it satisfies the patentability requirements.
D. Vascularisation technology
A new technical process for creating blood-vessel networks within engineered tissue may be patentable.
E. Complete bioengineered organs
A complete engineered organ presents more complicated questions. Patent protection would depend on the precise claims, technical contribution, biological characteristics, reproducibility, and compliance with ethical exclusions.
The fact that an organ is artificially manufactured does not automatically make every aspect of it patentable.
7. Human genetic engineering and patent restrictions
Regenerative medicine increasingly uses gene-editing technologies to improve the functioning of damaged cells.
For example:
Correcting mutations in cells intended for tissue repair.
Modifying immune cells.
Improving cellular survival.
Developing genetically modified regenerative tissues.
The distinction between somatic-cell modification and germline modification is legally significant.
Somatic-cell modification: A technique directed at non-reproductive cells may potentially qualify for patent protection, subject to ordinary requirements and other applicable restrictions.
Germline modification: Article 1349(4)(2) excludes methods for modifying the genetic integrity of human germline cells from patent rights.
Human cloning: Methods of cloning human beings and human clones are also excluded.
Therefore, a regenerative-organ patent application should clearly identify the biological material involved, the target cells, the intended technical result, and whether the process affects germline cells.
USPTO+1
8. Important Russian case laws and judicial decisions
There is an important research limitation: Russian reported judicial practice does not establish a substantial body of decisions specifically concerning patents for complete bioengineered human organs. Nevertheless, decisions concerning genetic engineering, biomedical inventions, and pharmaceutical patents provide relevant legal principles.
Case 1. Intellectual Property Court, 15 June 2020 – Case No. СИП-960/2019
Directly relevant to biotechnology patent exclusions
Court: Court for Intellectual Property Rights of the Russian Federation.
Subject: Refusal of patent protection for an invention involving modification of the genetic integrity of human germline cells.
Legal provision: Article 1349(4)(2) of the Civil Code.
Legal principle:
The Court upheld Rospatent's conclusion that the claimed invention involved modification of the genetic integrity of human germline cells and therefore could not receive patent protection.
The applicant argued, among other things, that the restrictions could impede the development of genetic therapies for hereditary diseases.
The Court did not accept that argument as a reason to disregard the statutory exclusion.
Importance for regenerative-organ patents:
This decision establishes an important boundary for regenerative biotechnology. An invention cannot escape the germline exclusion simply because its stated objective is therapeutic.
A technology intended to regenerate organs must therefore be distinguished carefully from a method involving prohibited germline modification.
Документы ленты ПРАЙМ: ГАРАНТ.РУ
Case 2. Rospatent decision, 25 July 2025 – Application No. 2019121518/63
Subject: Patent concerning a method of obtaining biological material for genetic testing in preimplantation genetic testing programmes involving human embryos.
Legal provisions: Articles 1349, 1350 and 1398 of the Civil Code.
Legal principle:
The decision examined the patentability of a technical method involving biological material obtained in connection with human embryos.
It also considered the requirements of novelty, inventive step, sufficient disclosure, and the statutory restrictions applicable to human embryos.
Importance:
This decision illustrates that inventions involving embryo-related biological material require careful examination of the actual technical subject matter.
Not every invention connected with embryology is automatically prohibited. The precise method and whether it involves an excluded commercial or industrial use of human embryos are important.
This distinction is relevant to regenerative-organ research involving stem cells and tissue development.
ГАРАНТ
Case 3. Nativa LLC v. Celgene Corporation – Case No. A40-71471/2017
Subject: Patent dispute involving lenalidomide, a pharmaceutical substance.
Relevant provisions: Articles 1358 and 1362 of the Civil Code.
Legal significance:
This pharmaceutical patent dispute is relevant by analogy rather than as a regenerative-organ case.
It illustrates the importance of distinguishing a separately developed technical invention from the commercial exploitation of an existing patented invention.
Application to regenerative medicine:
Suppose a biotechnology company develops a new scaffold that uses a separately patented biomaterial. Its patent on the scaffold does not automatically give it permission to exploit the underlying patented material.
Similarly, a patent covering a regenerative-cell manufacturing process does not automatically authorise the use of another company's patented growth factor, bioreactor, or biomaterial.
Law Gratis
Overall case-law observation: The first case provides a direct judicial interpretation of the genetic-integrity exclusion. The second concerns embryo-related biotechnology. The third supplies an analogy for patent exclusivity. None should be misrepresented as a judgment directly deciding ownership of a complete artificial human organ.
9. Ownership of regenerative-organ inventions
Ownership is an important issue when regenerative organs are developed through cooperation between universities, hospitals, scientists, and biotechnology companies.
Under Russian patent law, the following distinctions apply:
A. Inventorship
The natural persons who actually contribute to the creation of the technical invention are recognised as inventors.
Article 1348 addresses co-authorship. Multiple researchers may qualify as co-inventors when they make creative contributions to the invention.
B. Employer ownership
Article 1370 governs service inventions. Where an employee develops a patentable invention in connection with employment duties or a specific employer assignment, the employer may obtain the exclusive right under the statutory conditions.
C. University research
Where a university laboratory develops a new regenerative-organ scaffold or cellular manufacturing process, ownership depends on the employment relationship, research agreements, funding arrangements, and applicable statutory rules.
D. Commercial licensing
Biotechnology companies may obtain licences to manufacture and commercialise patented regenerative technologies.
Importantly, ownership of a patent on a manufacturing process does not mean ownership of a patient's body, donated biological material, or transplanted organ.
10. Patent infringement involving regenerative organs
Article 1358 of the Russian Civil Code governs the exclusive right to an invention and acts that constitute infringement.
Potential infringement situations include:
Manufacturing a patented regenerative scaffold without authorisation.
Commercially using a patented cell-culture process.
Importing products made using a protected invention.
Selling patented bioprinting equipment without permission.
Using a patented tissue-engineering composition commercially.
Unauthorised exploitation of patented organ-regeneration technology.
Article 1398 is also important because it provides grounds for invalidating a patent.
For example, a competitor may challenge a regenerative-organ patent if the claimed invention lacks novelty, inventive step, sufficient disclosure, or violates the exclusions in Article 1349.
11. Medical transplantation and regenerative-organ regulation
Patent registration and medical authorisation are separate legal matters.
Russia's organ-transplantation framework includes:
Law of the Russian Federation No. 4180-I of 22 December 1992, concerning the transplantation of human organs and tissues.
Federal Law No. 323-FZ of 21 November 2011, concerning the fundamentals of protecting citizens' health.
Federal Law No. 180-FZ of 23 June 2016, concerning biomedical cellular products.
These laws address different aspects of biological-material use, transplantation, healthcare, and cellular products.
For example, a company might successfully obtain a patent for a new artificial liver scaffold. That patent does not automatically authorise the company to conduct human clinical trials or manufacture and market the resulting medical product.
The applicable regulatory approvals and clinical requirements must still be satisfied.
12. International patent protection and Russia
Regenerative-organ technologies may also require international intellectual-property protection.
Relevant international instruments include:
| International instrument | Relevance |
|---|---|
| TRIPS Agreement | Minimum standards of patent protection |
| Paris Convention | Priority rights in patent applications |
| Patent Cooperation Treaty (PCT) | International patent application procedure |
| European Patent Convention | Comparative patentability framework |
| Convention on Human Rights and Biomedicine | Comparative ethical framework where applicable |
The PCT allows applicants to pursue patent protection in multiple countries through an international filing procedure. It does not itself grant a worldwide patent.
Russia's national patent requirements and exclusions continue to apply when protection is sought in Russia.
13. Major legal challenges
The development of regenerative-organ patents creates several unresolved or difficult legal questions.
1. Artificial organ ownership
Whether a complete bioengineered organ should be protected as a product, a combination of components, or a manufacturing process requires careful claim drafting.
2. Human biological material
The relationship between donor consent, biological-material use, confidentiality, and commercial exploitation requires separate legal analysis.
3. Patent versus public health
Exclusive patent rights must be considered alongside public-health interests, access to medical treatment, and statutory licensing mechanisms.
4. AI-generated organ designs
When artificial intelligence assists in designing a regenerative organ, questions arise concerning human inventorship and the identification of the actual creative contribution.
5. Genetic modification
Somatic-cell engineering and germline modification must not be treated as legally equivalent.
6. Cross-border biotechnology research
International collaboration can create conflicts involving ownership of research results, biological-material transfers, patent priority, confidentiality, and regulatory approval.
7. Insufficient disclosure
An application that merely describes an intended artificial organ without sufficiently explaining how a specialist can reproduce the claimed technical invention may face patentability objections.
14. Practical example
Consider a Russian biotechnology company developing a bioengineered kidney.
Impresiones 3D: Plantillas, prótesis dentales y hasta órganos construyen el futuro del 3D | WIRED
The company develops five technologies:
| Innovation | Possible legal treatment |
|---|---|
| Kidney-supporting scaffold | Patentable invention |
| Specialised bioink | Patentable invention |
| Bioprinting machine | Invention or utility model |
| Stem-cell differentiation process | Potentially patentable |
| Human germline modification method | Excluded under Article 1349 |
The company files an application with Rospatent.
The application must adequately describe the invention, its technical features, and how it can be implemented. Rospatent examines the application under the applicable patent rules.
If a patent is granted, the company obtains the relevant exclusive rights. However, it must separately comply with medical-product, cellular-product, transplantation, clinical-research, and other applicable regulations.
This example demonstrates that patent protection, ethical legality, and medical authorisation are three distinct legal questions.
15. Suggestions for strengthening Russian regenerative-organ patent law
Several legal developments could improve the regulatory framework:
Establish clearer patent examination guidance for 3D-bioprinted organs.
Clarify the distinction between patentable engineered tissues and excluded human biological subject matter.
Develop transparent standards for stem-cell-related patent applications.
Strengthen donor-consent and biological-material traceability requirements.
Improve rules concerning collaborative university–industry inventions.
Clarify inventorship issues involving AI-assisted organ design.
Improve coordination between Rospatent and medical regulators.
Establish specialised guidance for cross-border regenerative medicine research.
16. Conclusion
Biotechnology regenerative-organ patent law in Russia is governed primarily by Part IV of the Civil Code, particularly Articles 1349, 1350, 1358, 1363, 1370, and 1398.
Russian law permits patent protection for qualifying technological innovations in regenerative medicine, including engineered scaffolds, cell cultures, biomaterials, bioprinting systems, and organ-regeneration processes.
However, patent protection is restricted by ethical exclusions relating to human cloning, germline genetic modification, and industrial or commercial use of human embryos.
The Intellectual Property Court's decision of 15 June 2020 in Case No. СИП-960/2019 is particularly significant because it demonstrates that therapeutic objectives do not automatically override statutory restrictions on genetic engineering.
Ultimately, Russia's legal framework seeks to distinguish legitimate technological innovation from prohibited biological practices while maintaining separate requirements for patent registration, medical safety, and transplantation.
17. Important legal research sources
Russian Civil Code – Part IV (official Rospatent publication).
Federal Law No. 180-FZ – Biomedical Cellular Products.
Rospatent – Registration of an invention and grant of a patent.
Intellectual Property Court decision – Case No. СИП-960/2019.
Rospatent decision of 25 July 2025 – Application No. 2019121518/63.
Russian intellectual-property dispute statistics and recent litigation developments.
Academic qualification: This is a legal research overview, not an assertion that Russia has a dedicated regenerative-organ patent statute or a settled body of artificial-organ patent judgments. The case-law discussion distinguishes direct biotechnology decisions from analogous pharmaceutical patent litigation.

comments